Immunitybio slumps as FDA declines to approve bladder cancer treatment

Immunitybio Inc IBRX.O said the U.S. Food and Drug Administration has declined to approve its marketing application for a type of bladder cancer treatment, sending its shares down more than 50% in premarket trading on Thursday.